Literature DB >> 8480373

Molecular characterization of the dopamine transporter.

B Giros1, M G Caron.   

Abstract

Neurotransmission, which represents chemical signalling between neurons, usually takes place at highly differentiated anatomical structures called synapses. To fulfill both the time and space confinements required for optimal neurotransmission, highly specialized proteins, known as transporters or uptake sites, occur and operate at the presynaptic plasma membrane. Using the energy provided by the Na+ gradient generated by the Na+/K(+)-transporting ATPase, these transporters reuptake the neurotransmitters soon after their release, thereby regulating their effective concentrations at the synaptic cleft and the availability of neurotransmitters for a time-dependent activation of both pre- and postsynaptic receptors. The key role these proteins play in normal neurotransmission is further emphasized when the physiological and social consequences of drugs that interfere with the function of these transporters, such as the psychostimulants (e.g. amphetamine and cocaine) or the widely prescribed antidepressant drugs, are considered. In this review, Bruno Giros and Marc Caron elaborate on the potential consequences of the recent molecular cloning of the dopamine and related transporters and summarize some of the interesting properties that are emerging from this growing family of Na(+)- and Cl(-)-dependent transporters.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480373     DOI: 10.1016/0165-6147(93)90029-j

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  144 in total

1.  Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptake.

Authors:  M Syringas; F Janin; B Giros; J Costentin; J J Bonnet
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

2.  Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.

Authors:  Tabea H Schauer; Maximilian Lochner; Gabor G Kovacs
Journal:  J Neural Transm (Vienna)       Date:  2012-06-05       Impact factor: 3.575

3.  Additive effects of the dopamine D2 receptor and dopamine transporter genes on the error-related negativity in young children.

Authors:  A Meyer; D N Klein; D C Torpey; A J Kujawa; E P Hayden; H I Sheikh; S M Singh; G Hajcak
Journal:  Genes Brain Behav       Date:  2012-06-28       Impact factor: 3.449

4.  Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder.

Authors:  Erica Bowton; Christine Saunders; Kevin Erreger; Dhananjay Sakrikar; Heinrich J Matthies; Namita Sen; Tammy Jessen; Roger J Colbran; Marc G Caron; Jonathan A Javitch; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

5.  Akt-dependent and isoform-specific regulation of dopamine transporter cell surface expression.

Authors:  Nicole K Speed; Heinrich J G Matthies; J Phillip Kennedy; Roxanne A Vaughan; Jonathan A Javitch; Scott J Russo; Craig W Lindsley; Kevin Niswender; Aurelio Galli
Journal:  ACS Chem Neurosci       Date:  2010-05-25       Impact factor: 4.418

6.  Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum.

Authors:  W Michael Caudle; Jason R Richardson; Minzheng Wang; Gary W Miller
Journal:  Neurotoxicology       Date:  2005-08       Impact factor: 4.294

7.  Methylation of the dopamine transporter gene in blood is associated with striatal dopamine transporter availability in ADHD: A preliminary study.

Authors:  Corinde E Wiers; Falk W Lohoff; Jisoo Lee; Christine Muench; Clara Freeman; Amna Zehra; Stefano Marenco; Barbara K Lipska; Pavan K Auluck; Ningping Feng; Hui Sun; David Goldman; James M Swanson; Gene-Jack Wang; Nora D Volkow
Journal:  Eur J Neurosci       Date:  2018-08       Impact factor: 3.386

8.  Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs.

Authors:  O Cases; C Lebrand; B Giros; T Vitalis; E De Maeyer; M G Caron; D J Price; P Gaspar; I Seif
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

9.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

10.  Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter.

Authors:  Manuel Miranda; Kalen R Dionne; Tatiana Sorkina; Alexander Sorkin
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.